Mankind Pharma enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


1,02,787	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2,547	1,929	2,098	2,640	1,380
273	261	236	213	188
6,312	6,312	8,511	207	170
1,06,825	—	—	—	—
3,765	4,383	6,413	−2,433	−1,210
₹2,587.82	—	—	—	—

24,167	22,873	23,080	9,783	7,794
26.1%	27.6%	36.9%	2.1%	2.2%
0.06×	—	—	—	—

6.95×	—	—	—	—
26.20×	—	—	—	—
33.70×	—	—	—	—
44.81×	—	—	—	—
15,379	14,278	12,207	10,335	8,749
4,077	3,617	3,018	2,535	1,901
3,170	2,731	2,397	2,137	1,575
—	3,121	2,413	2,152	1,813
2,384	2,384	1,893	1,770	981
—	2,271	1,874	1,765	972
—	737	520	382	832

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MANKIND₹2,490.00

Mankind Pharma Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA CIPLA TORNTPHARM LAURUSLABS BIOCON ALKEM LUPIN GLENMARKMcap ₹1.03L Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	1,02,787.2
- Cash, Equiv & ST Investments	1,380.3	2,640.1	2,098.2	1,929.0	2,546.6
+ Minority Interest	188.1	212.7	235.8	260.7	273.0
+ Total Debt	170.4	207.2	8,511.5	6,311.5	6,311.5
Enterprise Value	—	—	—	—	1,06,825.2
Net Debt (memo)	-1,209.9	-2,432.9	6,413.3	4,382.5	3,764.9
EV per Share	—	—	—	—	2,587.82

Total Capital	7,793.7	9,783.0	23,079.6	22,872.6	24,166.8
Total Debt/Total Capital	2.19	2.12	36.88	27.59	26.12
Total Debt/EV	—	—	—	—	0.06

EV/Sales	—	—	—	—	6.95
EV/EBITDA	—	—	—	—	26.20
EV/EBIT	—	—	—	—	33.70
EV/Free Cash Flow	—	—	—	—	44.81
Reference Items — Trailing FY Values
Sales	8,749.4	10,334.8	12,207.4	14,277.6	15,378.6
EBITDA	1,900.6	2,535.1	3,017.9	3,617.4	4,076.8
EBIT	1,574.7	2,136.8	2,396.7	2,731.2	3,169.6
Operating Cash Flow	1,813.3	2,152.4	2,413.4	3,121.3	—
Free Cash Flow	981.2	1,770.1	1,893.3	2,384.1	2,384.1
FCFF (free cash flow to the firm)	972.2	1,765.2	1,873.6	2,271.2	—
Capital Expenditure	832.1	382.3	520.1	737.2	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.